2024 Q2 Form 10-Q Financial Statement
#000173728724000041 Filed on May 13, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| Revenue | $0.00 | $22.00K |
| YoY Change | -100.0% | -57.69% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $16.09M | $17.27M |
| YoY Change | -13.16% | -8.56% |
| % of Gross Profit | ||
| Research & Development | $50.36M | $52.26M |
| YoY Change | -18.83% | -34.87% |
| % of Gross Profit | ||
| Depreciation & Amortization | $3.644M | $3.555M |
| YoY Change | 0.03% | 1.37% |
| % of Gross Profit | ||
| Operating Expenses | $71.43M | $69.53M |
| YoY Change | -11.33% | -29.86% |
| Operating Profit | -$71.43M | -$69.50M |
| YoY Change | -11.29% | -29.84% |
| Interest Expense | $4.988M | $5.433M |
| YoY Change | 32.03% | 163.87% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $5.073M | $4.504M |
| YoY Change | -506.16% | 1130.6% |
| Pretax Income | -$66.36M | -$65.00M |
| YoY Change | -14.91% | -34.15% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$66.36M | -$65.00M |
| YoY Change | -14.91% | -34.15% |
| Net Earnings / Revenue | -295454.55% | |
| Basic Earnings Per Share | -$0.35 | -$0.38 |
| Diluted Earnings Per Share | -$0.35 | -$0.38 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 170.9M shares | 169.1M shares |
| Diluted Shares Outstanding | 190.0M shares | 169.1M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $444.6M | $384.9M |
| YoY Change | -9.62% | -18.33% |
| Cash & Equivalents | $170.7M | $51.04M |
| Short-Term Investments | $274.0M | $333.8M |
| Other Short-Term Assets | $12.50M | $10.50M |
| YoY Change | 23.25% | 2.57% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $457.1M | $395.4M |
| YoY Change | -8.96% | -17.88% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $92.08M | $95.93M |
| YoY Change | -50.68% | -12.67% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $1.134M | $15.12M |
| YoY Change | -98.19% | -71.95% |
| Other Assets | $6.439M | $5.159M |
| YoY Change | -67.27% | -45.05% |
| Total Long-Term Assets | $189.8M | $191.0M |
| YoY Change | -29.42% | -28.04% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $457.1M | $395.4M |
| Total Long-Term Assets | $189.8M | $191.0M |
| Total Assets | $646.9M | $586.4M |
| YoY Change | -16.1% | -21.49% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $12.94M | $5.779M |
| YoY Change | 26.46% | -60.65% |
| Accrued Expenses | $24.37M | $25.03M |
| YoY Change | -44.94% | -43.91% |
| Deferred Revenue | $86.00K | |
| YoY Change | -68.5% | |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $37.31M | $30.89M |
| YoY Change | -31.83% | -48.15% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $7.551M | $5.173M |
| YoY Change | -91.91% | 242.58% |
| Total Long-Term Liabilities | $7.551M | $5.173M |
| YoY Change | -91.91% | 242.58% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $37.31M | $30.89M |
| Total Long-Term Liabilities | $7.551M | $5.173M |
| Total Liabilities | $131.8M | $125.0M |
| YoY Change | -10.95% | -19.16% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.694B | -$1.627B |
| YoY Change | 20.97% | 21.92% |
| Common Stock | $2.209B | $2.090B |
| YoY Change | 8.33% | 8.1% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $515.0M | $461.4M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $646.9M | $586.4M |
| YoY Change | -16.1% | -21.49% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$66.36M | -$65.00M |
| YoY Change | -14.91% | -34.15% |
| Depreciation, Depletion And Amortization | $3.644M | $3.555M |
| YoY Change | 0.03% | 1.37% |
| Cash From Operating Activities | -$63.59M | -$55.90M |
| YoY Change | 2.8% | -16.12% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | $8.000K |
| YoY Change | -100.0% | -99.23% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $74.61M | $22.14M |
| YoY Change | 327.63% | -80.57% |
| Cash From Investing Activities | $74.61M | $22.13M |
| YoY Change | 334.81% | -80.4% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 108.6M | $1.650M |
| YoY Change | 21.31% | -4.68% |
| NET CHANGE | ||
| Cash From Operating Activities | -63.59M | -$55.90M |
| Cash From Investing Activities | 74.61M | $22.13M |
| Cash From Financing Activities | 108.6M | $1.650M |
| Net Change In Cash | 119.6M | -$32.12M |
| YoY Change | 166.87% | -166.87% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$63.59M | -$55.90M |
| Capital Expenditures | $0.00 | $8.000K |
| Free Cash Flow | -$63.59M | -$55.91M |
| YoY Change | 2.32% | -17.39% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
86000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
86000 | usd |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://allogene.com/20240331#AccruedAndOtherLiabilitiesCurrent | |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://allogene.com/20240331#AccruedAndOtherLiabilitiesCurrent | |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
17267000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
18884000 | usd |
| CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
69526000 | usd |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
99122000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-69504000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-99092000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
5433000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2059000 | usd |
| CY2024Q1 | us-gaap |
Other Expenses
OtherExpenses
|
929000 | usd |
| CY2023Q1 | us-gaap |
Other Expenses
OtherExpenses
|
2935000 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
4504000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-876000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-65000000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-99968000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
28000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
3992000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-64972000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-95976000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.38 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.38 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.69 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.69 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
169128362 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
169128362 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
144563829 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
144563829 | shares |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
512233000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
794000 | usd |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
532000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
11924000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
856000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-65000000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
28000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
461367000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
666882000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
0 | usd |
| CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
603000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
18770000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1731000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-99968000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
3992000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
592010000 | usd |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-65000000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-99968000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11924000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
18770000 | usd |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
3555000 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
3507000 | usd |
| CY2024Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
2797000 | usd |
| CY2023Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-508000 | usd |
| CY2024Q1 | allo |
Operating Lease Noncash Expense
OperatingLeaseNoncashExpense
|
-55000 | usd |
| CY2023Q1 | allo |
Operating Lease Noncash Expense
OperatingLeaseNoncashExpense
|
207000 | usd |
| CY2024Q1 | allo |
Noncash Collaboration Revenue
NoncashCollaborationRevenue
|
14000 | usd |
| CY2023Q1 | allo |
Noncash Collaboration Revenue
NoncashCollaborationRevenue
|
20000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-929000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-2935000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
86000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1263000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-1445000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-45000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-118000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1057000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-5690000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
5686000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
0 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-3000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
8000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-626000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-55899000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-66639000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
8000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1035000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
5623000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
103272000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
143441000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
81131000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
35094000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
22133000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
112935000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
794000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
856000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
1731000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1650000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1731000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-32116000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
48027000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93447000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
72196000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
61331000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
120223000 | usd |
| CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
2409000 | usd |
| CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | usd |
| CY2024Q1 | allo |
Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities
NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities
|
3079000 | usd |
| CY2023Q1 | allo |
Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities
NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities
|
3137000 | usd |
| CY2024Q1 | us-gaap |
Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
|
3068000 | usd |
| CY2023Q1 | us-gaap |
Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
|
2965000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Description of Business<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The Company is developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. The Company’s engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. The Company believes this key difference will enable it to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company had cash and cash equivalents and investments of $397.3 million as of March 31, 2024. Since inception through March 31, 2024, the Company has incurred cumulative net losses of $1,627.2 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div>The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). | |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
397300000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1627200000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities as of the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div> | |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
391728000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
35000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
518000 | usd |
| CY2024Q1 | allo |
Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
|
391245000 | usd |
| CY2024Q1 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
45019000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
333821000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
12405000 | usd |
| CY2024Q1 | allo |
Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
|
391245000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
444589000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
245000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
756000 | usd |
| CY2023Q4 | allo |
Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
|
444078000 | usd |
| CY2023Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
78536000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
365542000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
0 | usd |
| CY2023Q4 | allo |
Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
|
444078000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
|
P2Y | |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
0 | usd |
| CY2023Q1 | us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
1000000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
29400000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
48400000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
|
1700000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
|
1700000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
150570000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
150562000 | usd |
| CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
54639000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
51084000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
95931000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
99478000 | usd |
| CY2018Q3 | allo |
Area Of New Office Building
AreaOfNewOfficeBuilding
|
68000 | sqft |
| CY2018Q3 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P127M | |
| CY2018Q3 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P7Y | |
| CY2020Q4 | us-gaap |
Tenant Improvements
TenantImprovements
|
5000000 | usd |
| CY2021Q4 | allo |
Additional Area Of New Office Building
AdditionalAreaOfNewOfficeBuilding
|
47566 | sqft |
| CY2018Q4 | allo |
Area Of New Office Building
AreaOfNewOfficeBuilding
|
14943 | sqft |
| CY2018Q4 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P124M | |
| CY2018Q4 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P7Y | |
| CY2018Q4 | allo |
Tenant Improvement Allowance
TenantImprovementAllowance
|
800000 | usd |
| CY2024Q1 | us-gaap |
Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
|
6000000 | usd |
| CY2023Q4 | us-gaap |
Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
|
6000000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6930000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6775000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
88916000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
88346000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
95846000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
95121000 | usd |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
38476305 | shares |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
3020000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
3181000 | usd |
| CY2024Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
867000 | usd |
| CY2023Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
691000 | usd |
| CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
3887000 | usd |
| CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
3872000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
3100000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
9436000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
12920000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
13163000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
13612000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
14076000 | usd |
| CY2024Q1 | allo |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
65385000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
128592000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
32746000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
95846000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0624 | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P8Y9M25D | |
| CY2020Q3 | us-gaap |
Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
|
P20Y | |
| CY2020Q3 | allo |
Lessee Finance Lease Payment Upon Contract Termination
LesseeFinanceLeasePaymentUponContractTermination
|
4300000 | usd |
| CY2024Q1 | us-gaap |
Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
|
900000 | usd |
| CY2024Q1 | us-gaap |
Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
|
2700000 | usd |
| CY2023Q4 | us-gaap |
Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
|
3600000 | usd |
| CY2024Q1 | allo |
Number Of Shares As Percentage Of Common Shares Outstanding
NumberOfSharesAsPercentageOfCommonSharesOutstanding
|
0.05 | |
| CY2024Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
9738364 | shares |
| CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
|
5200000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11900000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
18800000 | usd |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
38712332 | shares |
